0.14
+12.50%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Voyageur Pharmaceuticals
Its shares trade on TSX Venture under the ticker VM.V. It has been listed since 18 May 2012. In the fiscal year to 30 November 2025, it reported revenue of C$11,685 and a net loss of C$3.5m. At that date it held total assets of C$3.1m and shareholders' equity of C$1.3m.
Voyageur Pharmaceuticals Ltd. engages in exploring and development of barite, iodine, and fullerene Active Pharmaceutical Ingredient (API) minerals. The company is headquartered in Calgary, Alberta. The company went IPO on 2012-05-18. The firm is focused on the development of barium, iodine and carbon active pharmaceutical ingredients (API) and high-performance imaging contrast agents for the medical imaging marketplace. The firm owns a 100% interest in three barium sulfate (barite) projects, including the Frances Creek property, suitable in grade for the pharmaceutical marketplace, with additional interests in a high-grade iodine, lithium & bromine brine project located in Utah, United States of America. The Company’s product pipeline includes SmoothX 2.0%, MultiX Thick, MultiX Thin, HDX, LDX, VY-101, and VY-103.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 18 May 2012
- Website
- voyageurpharmaceuticals.ca ↗
Leadership
Pay as last reported
- Mr. Eric PommerIndependent Chairman of the Board, since 2022C$3,000
- Mr. Brent WillisPresident, Chief Executive Officer, Director, since 2017C$131,000
- Mr. Albert DeslauriersChief Financial OfficerC$32,400
- Mr. Bradly WillisChief Operating Officer, Director, since 2019C$125,500
- Dr. Iryna SaranchovaChief Science Officer
- Mr. Agustin GagoDirectorC$2,000
- Ms. Beth ShawDirector
- Mr. Trent AbrahamIndependent DirectorC$40,780
- Mr. Eugene FritzelIndependent DirectorC$4,000
- Mr. Ronald SiftonIndependent DirectorC$38,003
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company is focused on development of barium, iodine and carbon active pharmaceutical ingredients (API)
- Owns 100% interest in three barium sulfate (barite) projects including Frances Creek property
- Has additional interests in a high-grade iodine, lithium & bromine brine project in Utah
Weaknesses
- Sector and industry are listed as N/A
- Company is engaged in exploring and development of minerals, not pharmaceutical production
- Product pipeline includes various products but no specific market success is mentioned
Opportunities
- Potential to develop high-performance imaging contrast agents for medical imaging marketplace
- Frances Creek property is suitable in grade for pharmaceutical marketplace
- Additional interests in Utah project could provide access to high-grade iodine resources
Threats
- Company is focused on minerals exploration rather than pharmaceutical manufacturing
- No specific market success or revenue figures provided for products
- IPO was in 2012, which may indicate limited recent market activity
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.